{"id":"mitomycin-c-5-fluorouracil","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Hand-foot syndrome"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":{"chemblId":"CHEMBL105","moleculeType":"Small molecule","molecularWeight":"334.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mitomycin-C is an alkylating agent that cross-links DNA strands, preventing replication and transcription. 5-Fluorouracil (5-FU) is a pyrimidine antimetabolite that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"This combination of mitomycin-C and 5-fluorouracil works by inhibiting DNA synthesis and cell division through complementary mechanisms of alkylating damage and antimetabolite activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:24.788Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"},{"name":"Biliary tract cancer"}]},"trialDetails":[{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT04166318","phase":"PHASE2","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-01-02","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma","enrollment":252},{"nctId":"NCT07425054","phase":"PHASE2","title":"HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jennifer Dorth","startDate":"2026-03","conditions":"Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus","enrollment":33},{"nctId":"NCT01858025","phase":"EARLY_PHASE1","title":"Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-07","conditions":"Carcinoma of the Anal Canal","enrollment":25},{"nctId":"NCT05838391","phase":"NA","title":"Adaptive Radiation in Anal Cancer","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-05-18","conditions":"Anal Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT07097142","phase":"PHASE3","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2026-05-11","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":486},{"nctId":"NCT01226550","phase":"PHASE1, PHASE2","title":"Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2007-06","conditions":"Peritoneal Carcinosis (PC)","enrollment":18},{"nctId":"NCT07043543","phase":"NA","title":"Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)","status":"NOT_YET_RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2026-01-15","conditions":"Bladder Cancer","enrollment":120},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8","enrollment":49},{"nctId":"NCT07271355","phase":"PHASE3","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-01","conditions":"Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":129},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":"High-Risk Non-Muscle Invasive Bladder Cancer","enrollment":328},{"nctId":"NCT06783491","phase":"PHASE3","title":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-12-31","conditions":"Locally Advanced Colorectal Cancer","enrollment":1083},{"nctId":"NCT04216290","phase":"PHASE2","title":"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":95},{"nctId":"NCT05040815","phase":"PHASE2","title":"Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-05-11","conditions":"Anal Canal Cancer","enrollment":45},{"nctId":"NCT02701088","phase":"PHASE2","title":"Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Francois Baclesse","startDate":"2015-12","conditions":"Locally Advanced Anal Canal Cancer","enrollment":71},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT02710734","phase":"PHASE2","title":"Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2016-02-24","conditions":"Urothelial Carcinoma of the Bladder","enrollment":78},{"nctId":"NCT04719988","phase":"PHASE2","title":"Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-01-04","conditions":"Squamous Cell Carcinoma of the Anus Stage III","enrollment":55},{"nctId":"NCT06734663","phase":"NA","title":"Clinical Outcomes of Sutured Versus Sutureless Conjunctival Autograft in Primary Pterygium Excision","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-12-15","conditions":"Pterygium of Conjunctiva and Cornea, Pterygium of Both Eyes, Pterygium","enrollment":70},{"nctId":"NCT04241185","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-19","conditions":"Urinary Bladder Neoplasms","enrollment":520},{"nctId":"NCT00981656","phase":"PHASE2","title":"Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-11","conditions":"Bladder Cancer","enrollment":37},{"nctId":"NCT03018418","phase":"PHASE2","title":"Proton Therapy in Reducing Toxicity in Anal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jordan Kharofa","startDate":"2017-01-04","conditions":"Anus Neoplasms","enrollment":14},{"nctId":"NCT04230759","phase":"PHASE2","title":"Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group","status":"ACTIVE_NOT_RECRUITING","sponsor":"Goethe University","startDate":"2020-01-07","conditions":"Anal Cancer, Anal Carcinoma, Anal Cancer Stage III","enrollment":180},{"nctId":"NCT01581840","phase":"PHASE1, PHASE2","title":"Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-01","conditions":"Epidermoid Carcinoma, Anus","enrollment":45},{"nctId":"NCT04729205","phase":"PHASE1","title":"Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies","status":"TERMINATED","sponsor":"Lipomedix Pharmaceuticals Inc.","startDate":"2021-01-13","conditions":"Cancer, Gastro-Intestinal Intraepithelial Neoplasia","enrollment":9},{"nctId":"NCT03691441","phase":"PHASE4","title":"Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer","status":"UNKNOWN","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2018-01-05","conditions":"Oropharyngeal Cancer","enrollment":280},{"nctId":"NCT03617913","phase":"PHASE2","title":"Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-09-19","conditions":"Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8","enrollment":2},{"nctId":"NCT05374252","phase":"PHASE3","title":"Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2022-05-07","conditions":"Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma, Anal Canal Cancer","enrollment":102},{"nctId":"NCT05353582","phase":"PHASE2","title":"Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-06-01","conditions":"Colorectal Neoplasms, Colorectal Cancer, Colorectal Cancer Metastatic","enrollment":168},{"nctId":"NCT01324141","phase":"PHASE1","title":"Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03-18","conditions":"Anal Cancer","enrollment":6},{"nctId":"NCT02526953","phase":"PHASE3","title":"Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2016-01","conditions":"Anus Neoplasms, Carcinoma, Squamous Cell, Anus Diseases","enrollment":314},{"nctId":"NCT04370925","phase":"PHASE3","title":"Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2020-06-04","conditions":"Colorectal Cancer","enrollment":688},{"nctId":"NCT02015650","phase":"PHASE4","title":"Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck","status":"TERMINATED","sponsor":"Medical University Innsbruck","startDate":"2014-04","conditions":"Head and Neck Neoplasms","enrollment":4},{"nctId":"NCT01621217","phase":"PHASE1","title":"Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2012-06","conditions":"Locally Advanced Cancer in the Anal Region","enrollment":21},{"nctId":"NCT01671488","phase":"PHASE1, PHASE2","title":"A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer","status":"TERMINATED","sponsor":"Brown University","startDate":"2013-02","conditions":"Anal Cancer","enrollment":11},{"nctId":"NCT02716896","phase":"NA","title":"Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer","status":"TERMINATED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-05","conditions":"Muscle Invasive Bladder Cancer","enrollment":2},{"nctId":"NCT00423293","phase":"PHASE2","title":"Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2006-12","conditions":"Anal Cancer","enrollment":63},{"nctId":"NCT00276744","phase":"PHASE2","title":"Individualized Drug Treatment for Treating Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-10","conditions":"Pancreatic Cancer","enrollment":249},{"nctId":"NCT01705002","phase":"PHASE1","title":"Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.","status":"COMPLETED","sponsor":"Lipomedix Pharmaceuticals Inc.","startDate":"2012-10","conditions":"Cancer, Solid Tumor, Metastatic Colorectal Cancer (mCRC)","enrollment":88},{"nctId":"NCT01285778","phase":"PHASE2","title":"Vectibix for the Treatment of Anal Cancer","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2010-10","conditions":"Anal Squamous Cell Carcinoma","enrollment":58},{"nctId":"NCT02369939","phase":"PHASE3","title":"Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2014-12","conditions":"Anal Carcinoma","enrollment":118},{"nctId":"NCT01171482","phase":"PHASE2","title":"Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2015-11","conditions":"Carcinoma, Hepatocellular","enrollment":5},{"nctId":"NCT00003596","phase":"PHASE3","title":"Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1998-10","conditions":"Anal Cancer","enrollment":682},{"nctId":"NCT02989207","phase":"NA","title":"Surgical Approaches in Treating Uncontrolled Glaucoma in Black African and African-Caribbeans","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2016-08","conditions":"Primary Open Angle Glaucoma","enrollment":60},{"nctId":"NCT01843452","phase":"PHASE2","title":"Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2012-12","conditions":"Carcinoma of Anal Canal","enrollment":8},{"nctId":"NCT01953406","phase":"PHASE2","title":"The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Seoul National University Hospital","startDate":"2015-11","conditions":"Hepatocellular Carcinoma, Lung Metastasis","enrollment":""},{"nctId":"NCT00201396","phase":"PHASE3","title":"A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2003-08","conditions":"Nasopharyngeal Carcinoma","enrollment":480},{"nctId":"NCT02352792","phase":"NA","title":"Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2008-12","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":90},{"nctId":"NCT02205008","phase":"PHASE3","title":"Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer","status":"UNKNOWN","sponsor":"Kyungpook National University Hospital","startDate":"2012-10","conditions":"Advanced Gastric Cancer With Serosal Invasion","enrollment":230},{"nctId":"NCT01941966","phase":"PHASE2","title":"A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.","status":"COMPLETED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2010-11","conditions":"Anal Canal Cancer.","enrollment":51},{"nctId":"NCT00289445","phase":"PHASE1, PHASE2","title":"Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"1999-09","conditions":"Gastrointestinal Neoplasms, Neoplasm Metastasis","enrollment":""},{"nctId":"NCT00003018","phase":"PHASE2","title":"S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1997-09","conditions":"Pancreatic Cancer","enrollment":54},{"nctId":"NCT01327521","phase":"PHASE3","title":"Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Albert Koong","startDate":"2011-02","conditions":"Carcinoma, Hepatocellular","enrollment":""},{"nctId":"NCT01489566","phase":"PHASE3","title":"Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients","status":"UNKNOWN","sponsor":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","startDate":"2011-07","conditions":"Hepatocellular,Carcinoma","enrollment":300},{"nctId":"NCT01039181","phase":"PHASE2","title":"Calcitriol in Advanced Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"National Science and Technology Development Agency, Thailand","startDate":"2010-01","conditions":"Advanced Intrahepatic Cholangiocarcinoma","enrollment":28},{"nctId":"NCT00644215","phase":"NA","title":"Comparison of Subconjunctival 5-Fluorouracil (FU) Injection and Mitomycin C for Treatment of Early Bleb Failure","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2007-06","conditions":"Bleb","enrollment":40},{"nctId":"NCT00346489","phase":"PHASE4","title":"Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2004-09","conditions":"Glaucoma","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":108,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mitomycin-C/ 5-Fluorouracil","genericName":"Mitomycin-C/ 5-Fluorouracil","companyName":"Medical University Innsbruck","companyId":"medical-university-innsbruck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mitomycin-C and 5-Fluorouracil are used in combination with other treatments, such as radiation and chemoradiation, for conditions including muscle invasive bladder cancer and stage II bladder cancer. The exact mechanism of action of these drugs is not specified in the provided facts, but they are studied in clinical trials for various cancer indications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}